|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 11/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01/09/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 01/01/2023 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 04/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 26/08/2016 |
Günter von Au
CHM | Chairman | 75 | 27/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| +0.35% | +0.93% | +20.41% | +72.72% | 48.2B | ||
| -0.08% | -0.21% | +56.71% | +119.95% | 39.97B | ||
| +0.15% | +6.34% | +21.40% | +88.46% | 12.43B | ||
| +0.25% | -0.61% | -10.44% | +15.76% | 12.03B | ||
| +0.19% | 0.00% | +29.35% | +151.21% | 9.35B | ||
| +0.07% | +3.80% | +30.19% | +45.41% | 7.75B | ||
| +2.24% | +8.50% | +30.72% | +232.43% | 7.43B | ||
| +0.04% | +0.37% | +48.28% | -11.16% | 7.22B | ||
| -0.53% | -1.53% | -36.09% | +15.18% | 5.3B | ||
| Average | +0.27% | +1.89% | +21.17% | +81.11% | 15.54B | |
| Weighted average by Cap. | +0.23% | +1.30% | +28.63% | +87.39% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















